Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Prova di fase I di un farmaco sperimentale contro il vaiolo

9 settembre 2026 aggiornato da: SIGA Technologies

Uno studio esplorativo randomizzato, in doppio cieco, incrociato, di fase I sulla farmacocinetica di una singola dose orale di forma I rispetto alle capsule di forma V del composto anti-Orthopoxvirus ST-246® in volontari sani alimentati normalmente

The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.

Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

12

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Florida
      • Orlando, Florida, Stati Uniti, 32809
        • Orlando Clinical Research Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 50 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. 18 to 50 years
  2. Available for clinical follow-up duration of study.
  3. Able/willing to give written consent.
  4. Good general health; no clinically significant medical history.
  5. Refrain from taking any medications from screening through 72 hours after last dose.
  6. Adequate venous access.
  7. PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
  8. Meet Lab Criteria within 28 days prior to receipt of drug.
  9. Negative pregnancy test
  10. Non smokers
  11. No alcohol or caffeine
  12. Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study

Exclusion Criteria:

  1. Marked baseline prolongation of QT/corrected QT interval (QTc) interval (

  2. History of additional risk factors for Torsade de Pointes

  3. Clinically significant abnormal ECG

  4. Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval

  5. Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.

  6. History of any clinically significant conditions including:

    • Asthma
    • Diabetes mellitus
    • History of thyroidectomy or thyroid disease
    • Serious angioedema episodes
    • Head trauma resulting in a diagnosis of TBI other than concussion
    • Seizure or history of seizure
    • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
    • Malignancy
  7. Family history of idiopathic seizures

  8. History or presence of neutropenia or other blood dyscrasia

  9. Known Hepatitis B or Hepatitis C infection

  10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.

  11. Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.

  12. Known clinically significant chronic viral infection (or current clinically significant viral infection

  13. History of frequent or severe headaches or migraines

  14. Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection

  15. Woman who is pregnant or is breast-feeding or planning to become pregnant

  16. On any concomitant medications

  17. History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.

  18. Inability to swallow medication

  19. Body Mass Index above 35 or below 18,

  20. Current drug abuse or alcohol abuse.

  21. Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice

  22. Clinically significant lactose intolerance

  23. Received experimental drug within 30 days

  24. Vaccination within 30 days

  25. Total of more than 350 milliliters (mL) of blood drawn in 2 months

  26. Treatment with any immunosuppressant or immunomodulatory medication in 3 months

  27. Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol

  28. History or diagnosis that would affect absorption of study medication

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione incrociata
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Group ST-246 Form I (followed by Form V)

Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

Altri nomi:
  • Tecovirim

Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.

Altri nomi:
  • Tecovirim
Comparatore attivo: Group ST-246 Form V (followed by Form I)

Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).

Altri nomi:
  • Tecovirim

Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.

Altri nomi:
  • Tecovirim

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles.

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL).

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL).

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax)

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
Lasso di tempo: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles.

Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
Lasso di tempo: 4 weeks

Evaluated safety parameters included:

  1. physical examination/vital signs
  2. electrocardiograms (heart rate, PR interval, QRS duration, QT interval, and QTc Bazett)
  3. laboratory safety tests (hematology, chemistry, urinalysis)
  4. adverse events For a), b) and c), summary statistics (mean,SD, median, minm, maxm)for values, and changes from baseline(Day 1 pre-dose) to each timepoint, were measured and compared to laboratory normal reference ranges. Values for a)- d) were assigned grades according to DAIDS AE Grading Table. Any Grade of 3 or higher was considered severe and significant.
4 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Thomas C Marbury, MD, Orlando Clinical Research Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 agosto 2008

Completamento primario (Effettivo)

1 ottobre 2008

Completamento dello studio (Effettivo)

1 ottobre 2008

Date di iscrizione allo studio

Primo inviato

1 agosto 2008

Primo inviato che soddisfa i criteri di controllo qualità

5 agosto 2008

Primo Inserito (Stimato)

6 agosto 2008

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 settembre 2026

Ultimo verificato

1 settembre 2010

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SIGA-246-005
  • HHSN266200600014C (Altro numero di sovvenzione/finanziamento: NIAID)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .